All Blogs / Industries / Medical / Pharmaceutical / New


The Curse of Expertise

David Sackett, epidemiologist and evidence-based medicine proponent, has died this week. I'd heard of him, but I hadn't seen his editorial about being an expert in one's field. Not all experts have had the thoughts that he had aboutShow More Summary

Introducing GlobalLeaks

https://globaleaks.org/ GlobaLeaks is an open source project aimed at creating a worldwide, anonymous, censorship-resistant, distributed whistleblowing platform.

Pharmaceutical Industry Must Pay for Drug Take-Back Programs

In a setback to drug makers, the U.S. Supreme Court denied an industry request to review a lawsuit filed over a drug take-back program in Alameda County, California.

Consumers Sue Anthem for Denying Coverage for a Gilead Hepatitis C Drug

The controversy over the new crop of hepatitis C treatments has taken yet another turn as consumers are starting to file lawsuits against insurers that deny them access to the medicines.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on AstraZeneca, Glaxo and Lots More!!

Good morning, everyone, and nice to see you again. We have returned from the long holiday weekend, which we hope you all find enjoyable and refreshing. Nothing like an extended respite, yes? But now, of course, the usual routine of meetings, deadlines and whatever else has returned. Show More Summary

Targeting Proteins for Destruction

Here's an excellent new paper that's appeared in the preprint area of Science, Science Express. Jay Bradner and co-workers at Harvard/Dana-Farber report a new way to control protein function, and this one seems both very effective and...Show More Summary

Expanded Access Programs

Expanded Access ProgramsJuly 22-23, 2015 | Bethesda, MDwww.cbinet.com/expandedaccessNew draft legislation and widespread advocacy efforts aim to improve patients’ access to experimental unapproved medicines. CBI’s Expanded Access Programs...Show More Summary

Actavis Must Keep its Older Alzheimer’s Pill on the Market

A federal appeals court ruled that Actavis cannot pull an older Alzheimer’s drug from the market in order to switch patients to a newer, more expensive version before generic competition emerged.

EMA Upholds Recommendation to Suspend Drugs Over ‘Flawed’ Studies

The European Medicines Agency is sticking with a decision to recommend suspending the sale of hundreds of drugs that were authorized for use based on what it called “flawed” studies that were conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India.

A New Amination Reaction

Phil Baran and group have another big new synthetic methods paper out in Science, and it's well worth a look. It's a radical mechanism, based on some earlier work from the group, as you might guess from the conditions: Fe(acac) 2 and triethylsilane in ethanol. Show More Summary

Pharmalot.. Pharmalittle.. As the Weekend Nears: We’re Catching up on Amgen, Merck and Lots More!!

And so, another working week is about to draw to a close. Although we sense things are already slowing down since we have a long holiday weekend coming up on this side of the pond. In any event, this is our treasured signal to daydream about weekend plans and our agenda is rather modest. Show More Summary

A Few Thoughts on the CVS Health-Omnicare Deal

Well, the Bloomberg story from yesterday’s news roundup turned out to be true: CVS Health is acquiring Omnicare. Read the press release. This a great deal for CVS Health, which extends its leadership in specialty dispensing, expands into long-term care and assisted living, and enlarges its generic and brand buying power. Show More Summary

Nepal after the recent earthquakes: reconstruction and vaccine-preventable enteric diseases

In the wake of the recent devastating earthquakes, PLOS Medicine Consulting Editor Lorenz von Seidlein visited Nepal to assess outbreak risks. Lorenz travelled with Anuj Bhattachan, International Vaccine Institute, Seoul, Korea and guidance from Deepak C. Show More Summary

Malaria and Epstein-Barr Virus: A Lethal Combination

A recent study in PLOS Pathogens investigates how Epstein-Barr virus and malaria co-infection may create a lethal combination if the timing is right. Epstein-Barr virus and malaria are two infections that can each be controlled on their...Show More Summary

From Pharma to Farmer: FDA Wants Sales Data on Antibiotics for Livestock

The FDA has proposed a rule that would require drug makers to report the amount of antibiotics that are sold for use in different types of food-producing livestock.

Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru

The heated battle between drug makers and patient advocates over patents and access to medicines is moving to Peru, where several consumer groups are urging the government to issue a compulsory license for an HIV medicine sold by Bristol-Myers Squibb.

Guess What: Your Peers Are Already Reviewing You

Looks like there are biologists who are getting a chance to figure out what social media can do to communication in their field. Nature News reports on the response to a PNAS paper published late last year from the Mouse ENCODE consortium. Show More Summary

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on CVS, Antibiotics and More!!

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say 'Every brand new day should...Show More Summary

Crappy Antibodies: Available Now, and for the Foreseeable Future

I made a brief mention of this article yesterday, but I wanted to highlight it. It's a look, from Nature New, at the broader implications of the antibody problem in research. Antibodies are, of course, universal reagents in molecular biology assays. Show More Summary

Copyright © 2015 Regator, LLC